4.5 Review

Genital warts treatment: Beyond imiquimod

Journal

HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 14, Issue 7, Pages 1815-1819

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2018.1445947

Keywords

genital warts; imiquimod; early protein 7; interleukin 10

Funding

  1. Science and Technology Research program of Foshan city [2012AA100461]
  2. Foshan City Council Research Platform Fund [2015AG1003]
  3. Science and technology Department of Guangdong province [2012B03180003]
  4. National Natural Science Foundation of China [81472451]
  5. Science and Technology Research program of Guangdong province [2016A020213001]
  6. first affiliated hospital of Guangdong Pharmaceutical University

Ask authors/readers for more resources

Genital warts are one of the most common sexually transmitted diseases worldwide. The disease is a result of infection with low-risk types of human papillomaviruses, mostly type 6 and 11. Current therapies for genital warts are mainly ablative, or alternatively topical application of imiquimod cream and sinecatechin (polyphenon E) ointment to the warts. However, low patient compliance and high recurrence rate are significant problems for the treatment of genital warts by imiquimod and ablative therapies. We summarise recent literature in this area and propose combining imiquimod with other therapies to increase the efficacy of imiquimod.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available